Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF and High-dose Influenza Vaccine Co-administration in Older Adults
NCT05071313Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Geometric Mean Titers of Hemagglutination Inhibition Antibodies Against Each of the Four Influenza Vaccine Strains at Day 29 and Geometric Mean Titers of Prefusion F-protein Antibodies at Day 29. Started Oct 2021; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05071313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071313.